High-Risk Prostate Cancer: Local Therapy Matters

被引:0
作者
Liss, Adam L. [1 ]
Hamstra, Daniel A. [1 ]
机构
[1] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
关键词
combination brachytherapy; high-risk prostate cancer; local control;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, a large focus of the management of prostate cancer has been to de-intensify treatment. Strategies to reduce treatment include decreasing the number of radiation treatment (RT) sessions, omitting surgery or RT altogether for men not expected to die of prostate cancer, and eliminating PSA screening completely. These could be effective strategies to decrease overtreatment, reduce the adverse effects of screening and treatment, and ultimately help to decrease the cost of medical care. There remains a population of men, however, who are diagnosed with more aggressive, locally advanced prostate cancer for which the standard treatment options are lacking and intensification of treatment is needed. This review summarizes treatment options for men with high-risk prostate cancer, including radical prostatectomy, external-beam radiotherapy (EBRT), and androgen-deprivation therapy (ADT). The focus here, however, will be on examining strategies to improve outcomes though intensification of local therapy using a combination of brachytherapy, EBRT, and ADT.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 39 条
  • [1] DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study
    Barrett, T.
    Gill, A. B.
    Kataoka, M. Y.
    Priest, A. N.
    Joubert, I.
    McLean, M. A.
    Graves, M. J.
    Stearn, S.
    Lomas, D. J.
    Griffiths, J. R.
    Neal, D.
    Gnanapragasam, V. J.
    Sala, E.
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2012, 67 (03) : 778 - 785
  • [2] Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
    Froehner, Michael
    Wirth, Manfred P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (18) : 1755 - 1755
  • [3] Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy
    Bittner, Nathan
    Merrick, Gregory S.
    Butler, Wayne M.
    Galbreath, Robert W.
    Lief, Jonathan
    Adamovich, Edward
    Wallner, Kent E.
    [J]. BRACHYTHERAPY, 2012, 11 (04) : 250 - 255
  • [4] Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
    Bolla, Michel
    van Poppel, Hein
    Tombal, Bertrand
    Vekemans, Kris
    Da Pozzo, Luigi
    de Reijke, Theo M.
    Verbaeys, Antony
    Bosset, Jean-Francois
    van Velthoven, Roland
    Colombel, Marc
    van de Beek, Cees
    Verhagen, Paul
    van den Bergh, Alphonsus
    Sternberg, Cora
    Gasser, Thomas
    van Tienhoven, Geertjan
    Scalliet, Pierre
    Haustermans, Karin
    Collette, Laurence
    [J]. LANCET, 2012, 380 (9858) : 2018 - 2027
  • [5] External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
    Bolla, Michel
    Van Tienhoven, Geertjan
    Warde, Padraig
    Dubois, Jean Bernard
    Mirimanoff, Rene-Olivier
    Storme, Guy
    Bernier, Jacques
    Kuten, Abraham
    Sternberg, Cora
    Billiet, Ignace
    Lopez Torecilla, Jose
    Pfeffer, Raphael
    Cutajar, Carmel Lino
    Van der Kwast, Theodore
    Collette, Laurence
    [J]. LANCET ONCOLOGY, 2010, 11 (11) : 1066 - 1073
  • [6] Duration of Androgen Suppression in the Treatment of Prostate Cancer
    Bolla, Michel
    de Reijke, Theodorus M.
    Van Tienhoven, Geertjan
    Van den Bergh, Alphonsus C. M.
    Oddens, Jorg
    Poortmans, Philip M. P.
    Gez, Eliahu
    Kil, Paul
    Akdas, Atif
    Soete, Guy
    Kariakine, Oleg
    Van der Steen-Banasik, Elsbietha M.
    Musat, Elena
    Pierart, Marianne
    Mauer, Murielle E.
    Collette, Laurence
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) : 2516 - 2527
  • [7] Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer
    Boorjian, Stephen A.
    Karnes, R. Jeffrey
    Viterbo, Rosalia
    Rangel, Laureano J.
    Bergstralh, Eric J.
    Horwitz, Eric M.
    Blute, Michael L.
    Buyyounouski, Mark K.
    [J]. CANCER, 2011, 117 (13) : 2883 - 2891
  • [8] Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer
    Briganti, Alberto
    Joniau, Steven
    Gontero, Paolo
    Abdollah, Firas
    Passoni, Niccolo M.
    Tombal, Bertrand
    Marchioro, Giansilvio
    Kneitz, Burkhard
    Walz, Jochen
    Frohneberg, Detlef
    Bangma, Chris H.
    Graefen, Markus
    Tizzani, Alessandro
    Frea, Bruno
    Karnes, R. Jeffrey
    Montorsi, Francesco
    Van Poppel, Hein
    Spahn, Martin
    [J]. EUROPEAN UROLOGY, 2012, 61 (03) : 584 - 592
  • [9] The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer
    D'Alimonte, Laura
    Helou, Joelle
    Sherman, Christopher
    Loblaw, Andrew
    Chung, Hans T.
    Ravi, Ananth
    Deabreu, Andrea
    Zhang, Liying
    Morton, Gerard
    [J]. BRACHYTHERAPY, 2015, 14 (03) : 309 - 314
  • [10] Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial
    Denham, James W.
    Steigler, Allison
    Lamb, David S.
    Joseph, David
    Turner, Sandra
    Matthews, John
    Atkinson, Chris
    North, John
    Christie, David
    Spry, Nigel A.
    Tai, Keen-Hun
    Wynne, Chris
    D'Este, Catherine
    [J]. LANCET ONCOLOGY, 2011, 12 (05) : 451 - 459